5-Fluorouracil–Based Chemotherapy Enhances the Antitumor Activity of a Thymidylate Synthase–Directed Polyepitopic Peptide Vaccine
Authors:
- Pierpaolo CorrealePierpaolo Correale
- Maria Teresa Del VecchioMVMaria Teresa Del Vecchio
- Giuseppa Di GenovaGGGiuseppa Di Genova
- Gianni Gori SavelliniGSGianni Gori Savellini
- Marco La PlacaMPMarco La Placa
- Chiara TerrosiCTChiara Terrosi
- Marzio VestriMVMarzio Vestri
- Renato UrsoRURenato Urso
- Francois LemonnierFLFrancois Lemonnier
- Angelo AquinoAAAngelo Aquino
- Enzo BonmassarEBEnzo Bonmassar
- Giorgio GiorgiGGGiorgio Giorgi
Open Access
- 5 October 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 97 (19) , 1437-1445
Abstract
Background : Thymidylate synthase (TS), a key enzyme in DNA synthesis, is often overexpressed in cancer cells. Some chemotherapeutic agents, such as 5-fluorouracil (5-FU), act by inhibiting TS expression. We evaluated whether a novel 28-amino acid multiepitope peptide, TS/PP, that contains the sequences of three TS-derived epitopes with binding motifs for HLA-A(*)02.01 could induce a TS-directed cytotoxic T-lymphocyte (CTL) response with antitumor activity. Methods: TS/PP peptide immunologic activity in CTL lines derived from human leukocyte antigen (HLA)-A(*)02.01 + peripheral blood mononuclear cells (PBMCs) was tested in the presence of interleukin-2 and autologous TS/PP peptide-loaded dendritic cells. Immunologic and antitumor activities of TS/PP and its toxicity were also evaluated in vivo in HLA-A(*)02.01 transgenic (HHD) mice that were vaccinated with TS/PP, control, or TS-peptide cocktail and treated with or without 5-FU chemotherapy. The mice were also inoculated subcutaneously with TS-expressing EL-4/HHD lymphoma cells to assess immune response against these tumor cells. Results: TS/PP-specific CTL lines showed a TS-multiepitopic specificity and were able to kill TS + /HLA-A(*)02.01 + breast and colon carcinoma cells. The killing ability against target cells previously exposed to sublethal doses of 5-FU was statistically significantly greater than against untreated target cells (43.5% versus 26.5% at 25/1 effector to target ratio [Difference {diff} = 17.0]; 95% confidence interval [CI] = 12.6 to 20.4) for MDA-MB-231 breast carcinoma cells and 73.5 versus 48.5 (diff = 25.0; 95% CI = 16.2 to 33.8) for the SW-1463 colon carcinoma cells. HHD mice vaccinated with TS/PP manifested a TS-peptide-specific CTL response with no sign of autoimmunity or toxicity. Furthermore, treatment of these mice with 5-FU delayed or prevented the occurrence of tumors formed by inoculation with autologous (TS + )EL-4/HHD lymphoma cells. Conclusions: The multiepitopic TS/PP vaccine induces a tumor-specific immune response in mice and is especially potent when used in combination with 5-FU-based chemotherapy.Keywords
This publication has 15 references indexed in Scilit:
- In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouseBritish Journal of Cancer, 2003
- Treatment of colon and breast carcinoma cells with 5‐fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA‐A(*)02.01 restricted, CEA‐peptide‐specific cytotoxic T cells in vitroInternational Journal of Cancer, 2003
- High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side EffectsThe Journal of Immunology, 2002
- Distribution of Mutations in Human Thymidylate Synthase Yielding Resistance to 5-FluorodeoxyuridineJournal of Biological Chemistry, 2002
- In VitroGeneration of Cytotoxic T Lymphocytes Against HLA-A2.1 -Restricted Peptides Derived from Human Thymidylate SynthaseJournal of Chemotherapy, 2001
- Random Sequence Mutagenesis and Resistance to 5-Fluorouridine in Human Thymidylate SynthasesJournal of Biological Chemistry, 1998
- HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout MiceJournal of Experimental Medicine, 1997
- The role of thymidylate synthase as an RNA binding proteinBioEssays, 1996
- New targets for pyrimidine antimetabolites in the treatment of solid tumoursPharmacy World & Science, 1994
- Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytesEuropean Journal of Immunology, 1993